How should botulinum toxin (onabotulinumtoxinA) be administered for adult chronic anal fissure after at least 4 weeks of failed topical therapy when surgical lateral internal sphincterotomy is unsuitable or declined?

Botulinum Toxin for Chronic Anal Fissure

Inject 50-100 Units of botulinum toxin into the internal anal sphincter for chronic anal fissure after failed topical therapy, with injection either into each side of the fissure or out of the fissure site, performed under monitored anesthesia care. This approach achieves 75-95% healing rates with minimal risk of permanent incontinence compared to surgical sphincterotomy 1.

Dosing Protocol

The evidence strongly supports a specific dosing range:

• Standard dose: 50-100 Units is used by 90% of colorectal surgeons 2
• Lower doses (20-30 Units) show inferior healing rates of 73.8% with single injection 3
• Higher doses (100 Units) achieve 77.7% complete healing at 2 months 4

The optimal approach is to start with 50 Units and repeat with 50 Units at 2 months if healing is incomplete, which achieves overall healing rates of 86.9-93.9% 3, 4. This two-injection strategy is more effective than single lower-dose injection 5.

Injection Site Selection

The injection location significantly impacts outcomes, though the evidence shows trade-offs:

Two acceptable approaches exist:

1. Each side of the fissure (SF): Inject bilaterally flanking the fissure into the internal sphincter

   • Lower short-term healing but reduced recurrence rates 6
   • 64% of surgeons use internal sphincter injection 2

2. Out of the fissure (OF): Inject away from the fissure site

   • Higher short-term healing with low-dose BT (RR 1.20) 6
   • Higher recurrence risk (RR 1.89-2.08) 6

I recommend injection into each side of the fissure because while short-term healing may be slightly slower, the reduced recurrence rate is more important for long-term quality of life. The guideline acknowledges "the optimal location of injection (internal vs. external sphincter) remains controversial" 1, but the internal sphincter is the pathophysiologic target.

Administration Technique

Perform under monitored anesthesia care (MAC) - used by 56% of surgeons 2. This allows adequate sphincter relaxation for accurate injection while avoiding general anesthesia risks.

Inject into 4 quadrants around the anal canal circumference, as practiced by 53% of surgeons 2. This distributes the toxin effect evenly across the internal sphincter.

Expected Outcomes and Timeline

The healing trajectory follows a predictable pattern:

• 1-2 days: Chemical denervation begins 7
• 1 week: Intensity of effect peaks 7
• 2 months: 73-78% healing with single injection 3, 4
• 6 months: 86.9-93.9% healing after repeat injection if needed 3, 4
• Duration of effect: Approximately 3-4 months 7

Resting anal tone decreases significantly from baseline (77.1 ± 18.9 mmHg vs higher baseline, P < 0.0001) 4, which is the mechanism of fissure healing.

Critical Predictors of Success

Not all patients respond equally. Three factors predict healing:

1. Female gender (OR 0.48 for needing surgery) 8
2. Absence of chronic constipation (OR 0.09 for needing surgery) 8
3. Shorter constipation duration - less than 10 months predicts 88% accuracy for healing 8

Male patients with constipation >10 months should be counseled about higher failure rates and may warrant earlier consideration of lateral internal sphincterotomy 8.

Safety Profile

Botulinum toxin has a superior safety profile compared to sphincterotomy:

• Transient minor incontinence: 18% 9, resolving within 2 months 8
• No permanent incontinence in multiple studies 3, 8
• Minimal injection discomfort 9
• Return to activities: 1 day vs 14.8 days for sphincterotomy (P < 0.0001) 3

In contrast, lateral internal sphincterotomy causes permanent incontinence in 8-19.2% of patients 3, 8, which is a devastating quality of life impact.

Management of Treatment Failures

If healing is incomplete at 2 months:

1. Repeat injection with 50 Units - achieves 93.9% cumulative healing 4
2. Reassess at 6 months before considering surgery
3. Reserve lateral internal sphincterotomy for the 13-26% who fail two injections 3, 4

Second-line botulinum toxin after failed topical therapy (glyceryl trinitrate) still achieves 73% symptomatic improvement and 43% complete healing 9. This sequential approach (topical → botulinum toxin → surgery) avoids sphincterotomy in 85-90% of patients 9.

Concomitant Therapies

Do not routinely add:

• Manual dilatation (used by only 34% of surgeons) 2
• Fissurectomy (used by 38%) 2
• Topical muscle relaxants are not used uniformly 2

These additions lack evidence for improved outcomes and may increase complications.

Long-Term Outcomes

At 5 years, 73.8% remain healed without recurrence 8. The 26.2% who ultimately required sphincterotomy could be predicted by the factors above. No relapses occurred during average 71-month follow-up in one large series 4, suggesting durable healing when achieved.

Critical Caveats

Avoid botulinum toxin in:

• Off-midline fissures (evaluate for Crohn's disease, HIV, tuberculosis, malignancy) 1
• Patients with pre-existing sphincter compromise 1

The guideline emphasizes that botulinum toxin "should be considered acceptable options, even if not entirely proven" with "low morbidity profiles allow them to be used as first-line treatment" 1. However, 20+ years of subsequent research has validated this approach with healing rates of 75-95% 1 and excellent long-term safety 8, 4.

Repeat injection at 3-month intervals has not been evaluated for safety 7, so maintain at least 3-month intervals between treatments.